Atara Biotherapeutics (ATRA) Cash & Current Investments (2013 - 2026)

Atara Biotherapeutics (ATRA) has 14 years of Cash & Current Investments data on file, last reported at $8.4 million in Q1 2026.

• Quarterly Cash & Current Investments fell 39.6% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (down 39.6% YoY) and the FY2025 annual result came in at $8.5 million, down 66.31% from the prior year.
• Cash & Current Investments fell to $8.4 million in Q1 2026, from $8.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $301.8 million in Q1 2022 to a low of $5.7 million in Q3 2025.
• A 5-year average of $65.1 million and a median of $46.2 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 128.48% — and 2025, when it sank 87.68%.
• Tracing ATRA's Cash & Current Investments over 5 years: stood at $242.8 million in 2022, then plunged by 78.7% to $51.7 million in 2023, then slumped by 51.33% to $25.2 million in 2024, then sank by 66.31% to $8.5 million in 2025, then decreased by 1.44% to $8.4 million in 2026.
• The last three Cash & Current Investments figures came in at $8.4 million (Q1 2026), $8.5 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.